Gilead Sciences Eyes $2 Billion Deal for Autoimmune Biotech Ouro Medicines

Gilead Sciences eyes up to $2B deal for autoimmune biotech Ouro Medicines, with $1.5B upfront + milestones, amid strong stock & deal spree.